CD19 and renal cell adenocarcinoma: CD20 and CD19 are considered pan-markers for B-cells.12 Future analyses of the marker- and gene expression status of the B-cells in the poor-prognosis subset of RCC should therefore give some guidance about the possible relevance of the above described mechanisms for the observed survival-associations in this study.